BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38578436)

  • 1. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
    Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
    Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
    Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
    Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
    Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer.
    Pradhan MC; Kazaure HS; Wang F; Zambeli-Ljepovic A; Perkins JM; Stang MT; Scheri RP
    J Surg Res; 2021 Aug; 264():37-44. PubMed ID: 33765509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
    Tian T; Kou Y; Huang R; Liu B
    Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
    Rosario PW; Mourão GF
    Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
    Tian T; Qi Z; Huang S; Wang H; Huang R
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of initial stimulation thyroglobulins and staging system by revised ATA guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation.
    Kim MH; Ko SH; Bae JS; Lim DJ; Baek KH; Lee JM; Kang MI; Cha BY
    Clin Nucl Med; 2012 Nov; 37(11):1069-74. PubMed ID: 22996253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
    Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
    Xing Z; Qiu Y; Li Z; Zhang L; Fei Y; Zhu J; Su A
    BMC Surg; 2021 Jan; 21(1):53. PubMed ID: 33482804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
    Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
    Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
    [No Abstract]   [Full Text] [Related]  

  • 20. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.